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Abstract
Background: Pancreatic cancer has significant morbidity and mortality worldwide. Good prognosis relies on an early 
diagnosis. The purpose of this study was to develop techniques for identifying cancer biomarkers in the serum of 
patients with pancreatic cancer.
Methods: Serum samples from five individuals with pancreatic cancer and five individuals without cancer were 
compared. Highly abundant serum proteins were depleted by immuno-affinity column. Differential protein analysis 
was performed using 2-dimensional differential in-gel electrophoresis (2D-DIGE).
Results: Among these protein spots, we found that 16 protein spots were differently expressed between the two 
mixtures; 8 of these were up-regulated and 8 were down-regulated in cancer. Mass spectrometry and database 
searching allowed the identification of the proteins corresponding to the gel spots. Up-regulation of mannose-binding 
lectin 2 and myosin light chain kinase 2, which have not previously been implicated in pancreatic cancer, were 
observed. In an independent series of serum samples from 16 patients with pancreatic cancer and 16 non-cancer-
bearing controls, increased levels of mannose-binding lectin 2 and myosin light chain kinase 2 were confirmed by 
western blot.
Conclusions: These results suggest that affinity column enrichment and DIGE can be used to identify proteins 
differentially expressed in serum from pancreatic cancer patients. These two proteins 'mannose-binding lectin 2 and 
myosin light chain kinase 2' might be potential biomarkers for the diagnosis of the pancreatic cancer.
Background
Pancreatic ductal adenocarcinoma is the most common
malignancy of the pancreas that arises from the ductal
epithelium of the pancreas. Despite many efforts, con-
ventional treatment approaches, including surgery, radia-
tion, chemotherapy, or combinations of these, have had
little impact on the outcome of this lethal disease. The
overall prognosis for the disease is dismal: after resection,
the median survival does not exceed 2 years with a 5-year
survival rate less than 20% [1-3]. One major reason for
this poor outcome is the late diagnosis of the disease and
only about 10-20% of patients are eligible for resection
[4,5]. The overall 5-year survival rate of patients with
curative resection of pancreatic cancer is 25%. This can
be improved to 40% when the tumor is operated in its
early stages, for example, when the tumor size is less than
2 cm and there are no lymph node metastases [6,7].
Therefore, early diagnosis of pancreatic cancer is of para-
mount importance in clinical practice.
Serum is a preferred specimen for the early diagnosis of
malignant tumors, because samples are available readily
by less invasive methods. Although extensive efforts have
been focused on finding candidates for serum tumor
markers and many candidates have been listed, none of
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Page 2 of 9them has yet been proven to be clinically useful. These
tumor markers are neither tumor-specific nor pancreatic
cancer-specific. CA19-9 is the most widely used tumor
marker in pancreatic cancer, however the specificity is
low. It may also be elevated in benign conditions includ-
ing pancreatitis, hepatitis and cirrhosis, as well as in gas-
tric cancer and colon cancer [8-10]. Other markers such
as CEA, CA125 are being studied, but not specifically for
the diagnosis of pancreatic cancer.
Recent advances in proteomic technologies, including
2-dimentional differential in-gel electrophoresis (2D-
DIGE) and improved MS, have provided new opportuni-
ties for identifying biomarkers and therapeutic targets for
cancer treatment. DIGE is effective in separating complex
protein samples and in quantifying protein levels
between samples. Proteins of interest can then be identi-
fied by tandem mass spectrometry (MS/MS). By loading
an internal common standard sample labeled with a dif-
ferent fluorescent dye, gel-to-gel variations are cancelled
out and quantitative proteomic profiling can be achieved
across multiple samples [11].
A major problem is that the most abundant serum pro-
teins like albumin and immunoglobin comprise over
eighty-five percent of total serum protein. Proteins of
interest are probably present at significantly lower con-
centrations. The most abundant serum proteins make it
difficult to run two-dimensional gels reproducibly. These
abundant proteins also limit the amount of serum that
can be loaded onto 2-D gels for analysis, and mask differ-
ential expression of lower-abundance proteins with simi-
lar molecular weights and isoelectric points [12,13]. In
this study, we used an immuno-affinity column that effec-
tively removed the highest abundance proteins from the
serum of patients with pancreatic cancer and non-can-
cer-bearing control individuals. Samples were then ana-
lyzed by DIGE and MS/MS. These techniques had
allowed for the identification and characterization of a
number of potential protein biomarkers. Differential
expression of the proteins of interest had been confirmed
using western blot.
Methods
Patients and Serum sample preparation
Blood samples were obtained from five pancreatic cancer
patients and five non-cancer-bearing individuals, and
samples from an additional 16 pancreatic cancer and 16
non-cancer-bearing donors were collected for the further
validation at Zhongshan Hospital (Fudan University,
Shanghai, China). Informed consent was obtained from
all donors and the protocol was approved by the institu-
tional review board of the Zhongshan Hospital. Blood
samples (5 ml) were obtained from the donors in tubes
without additive and allowed to clot at room temperature
for 40 min. Serum was separated by centrifugation at
3000 rpm for 10 min and stored at -80°C until use.
Serum samples were processed using the Agilent Multi-
ple Affinity Removal Column (Multiple Affinity Removal
Column, 4.6 mm × 50 mm; Agilent Technologies, Palo
Alto, CA), that selectively removes albumin, IgG, IgA,
antitrypsin, transferrin and haptoglobin from the serum
sample. Samples were processed according to the manu-
facturer's instructions. For each sample, a low abundance
fraction was collected and buffer-exchanged into 10 mM
Tris-HCl pH 7.4 using 5000 Da molecular weight cutoff
spin concentrators (Agilent Technologies, Palo Alto, CA).
Protein quantification was performed using the Coo-
massie protein assay reagent (Pierce Biotechnology,
Rock-ford, absorbance at 595 nm), with a Bradford pro-
tein assay. The bovine serum albumin was used as stan-
dard protein. Approximately 90% of total serum protein
was removed by this method.
Fluorescence labeling
The rationale for using a pooled internal standard with
DIGE to control for gel-to-gel variation has been
described previously in detail [11]. A total of 50 μg of
serum protein was labeled at a minimal level with one of
three CyDye DIGE Fluors (GE Healthcare, Piscataway,
NJ). Individual serum samples from 3 groups (pooled
internal standard, cancer and control) were labeled with
Cy2, Cy3 and Cy5 respectively. The three dyes were
designed to ensure that proteins common to each sample
had the same relative mobility regardless of the dye used
to tag them. CyDyes were reconstituted in anhydrous
DMF and combined with samples at a ratio of 400 pmol
of CyDye to 50 μg of protein. Labeling was performed on
ice and in the dark for 30 min. The reaction was then
quenched by incubating with 1.5 μL of 10 mM lysine on
ice and in the dark for 10 min.
2D Gel Electrophoresis and Imaging
Three labeled protein samples (standard, cancer, and
control sample) were combined. 1 mg of unlabeled
pooled standard sample was processed separately by 2 D
gel electrophoresis for purposes of protein identification.
Proteins were focused on 13 cm, 3-10 immobilized pH
gradient (IPG) strips (GE Healthcare, Piscataway, NJ)
using an IPGphor focusing apparatus (GE Healthcare,
Piscataway, NJ). IPG strips were then equilibrated in
equilibration buffer (50 mM Tris-HCl, 6 M urea, 30%
glycerol, 2% SDS) supplemented with 1% dithiothre-
itol(DTT) to maintain the fully reduced state of proteins,
followed by 2.5% iodoacetamide to prevent reoxidation of
thiol groups during electrophoresis. Proteins were sepa-
rated on 10%Tris-glycine gels (ProtoGel, National Diag-
nostics, Atlanta, GA) using an Ettan DALT II System (GE
Healthcare, Piscataway, NJ). The gels were scanned with a
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Spot detection, quantification and image matching were
performed with Decyder software (GE Healthcare Bio-
Sciences). Triplicate gels were run for each sample to
reduce gel-to-gel variations. The emission filters were
Blue 488 nm (Cy2), Green 532 nm(Cy3), and Red 633
nm(Cy5). The 2-D gel containing 1 mg of unlabeled
pooled standard sample was fixed in 30% methanol, 7.5%
acetic acid, and then Coomassie stained (Colloidal Blue
stain kit, Invitrogen, Carlsbad, CA), and scanned with the
same imager, with an excitation wave length of 633 nm.
We ran triplicate gels for each sample to reduce the gel-
to-gel variations.
DIGE Analysis
Relative protein quantification across pancreatic cancer
and control samples was performed using DeCyder Dif-
ferential In Gel Analysis and Biological Variance Analysis
software (Version 4.0, GE Healthcare, Piscataway, NJ).
The Cy2-labeled pooled internal standard on every gel
allowed accurate relative quantitation of protein spot fea-
tures across different gels. Student's t-test and one-way
ANOVA were used to calculate significant differences in
relative abundances of protein spot-features in cancer
sera compared with control sera.
In-gel Digestion
Protein spot-features that were significantly increased or
decreased (p < 0.05) in all cancer samples compared to
control samples were chosen for further analysis. In-gel
digestion was performed for protein spots excised by an
automated spot picker (SpotPicker; GE Healthcare Bio-
Sciences). The 2 mm diameter gel plugs were washed in
Milli-Q water for 15 min, and then washed three times in
25 mM NH4HCO3, 50% CH3CN for 30 min while vortex-
mixing. Gel plugs were then dehydrated in 100% CH3CN
for 10 min while vortex-mixing. The supernatant was
removed, and gel plugs were allowed to air-dry for 1 h.12
μg of 1.5 μM trypsin (sequence-grade trypsin, Promega,
Madison, WI) suspended in 25 mM NH4HCO3 was
added, and gel plugs were allowed to re-hydrate for 30
min on ice. Gel plugs were placed at 37°C and allowed to
digest overnight. 96-well plates were then gently centri-
fuged, and the supernatant was taken for MALDI-TOF or
LTQ MS analysis.
MS/MS and Data Analysis
Differentially expressed protein spots were excised from
the gels. Trypsin peptide solutions were mixed at a 1:1
ratio with 5 mg/mL R-cyano-4-hydroxy-cinnamic acid
(CHCA) matrix in 0.3% TFA, and spotted on stainless
steel MALDI sample plates (Applied Biosystems,
Framingham, MA). Peptide mixtures were then analyzed
using MALDI-TOF (4700 Proteomics Analyzer, Applied
Biosystems, Framingham, MA) or LTQ MS (Thermo-
Quest, San Jose, CA, USA) coupled with a Surveyor
HPLC system (ThermoQuest). In MALDI-TOF MS, pro-
tein identification was performed using Global Proteome
Server Explorer software (Applied Biosystems, Framing-
ham, MA) with the NCBI Reference Sequence (RefSeq
Release 5) human protein database. Identification was
assigned to a protein spot feature if the protein score was
calculated to be greater than 50, correlating to a confi-
dence interval of 99%. In LTQ MS, the full scan ranged
from M/Z 400 to 2000. Protein identification using MS/
MS raw data was performed with SEQUEST software
(University of Washington, licensed to Thermo Finnigan)
based on the database of Swiss-prot (release 54.7). A rela-
tive molecular mass of 57 (57D) was added to the average
molecular mass of cysteines in MS/MS data searching.
Protein identification results were filtered with the
Xcorr(1+≥ 1.9, 2+≥ 2.2, 3+≥ 3.75 ) and DelCn(≥ 0.1).
(Experiments of 2 D gel electrophoresis and protein identi-
fication by MS were completed by the Shanghai Institutes
for Biological Sciences, Research Center for Proteome
Analysis).
Western Blot Analysis
Serum samples from an additional 16 pancreatic cancer
and 16 non-cancer-bearing donors were collected for the
western blot analysis. These serum samples were non-
immuno-depleted and protein concentrations were
determined using Bradford reagent (Sigma) according to
the manufacturer's instructions. Equal amounts of pro-
tein (30 μg) were mixed with loading buffer ( 62.5 mM
Tris-HCl, pH6.8, 10% glycerol, 2% SDS, 2%β-mercapto-
ethanol and bromphenol blue), boiled for 5 min and sub-
jected to SDS-PAGE. Proteins were transferred to
polyvinylidene difluoride membranes (Millipore, Bed-
ford, MA). The membranes were blocked with 5% fat-free
dry milk in Tris-buffered saline containing 0.05% Tween
20(TBST) for 1 h at room temperature and incubated
overnight with primary antibodies in TBST with 1%
bovine serum albumin. After washing with TBST for
three times, the membranes were further incubated for 1
h at room temperature with corresponding horseradish
peroxidase-conjugated secondary antibody in appropri-
ate dilution and then followed by washing twice with
TBST and once with TBS. The immuno-reactive protein
bands were visualized by ECL kit (Pierce). Anti-MBL2,
anti-MLCK2 and anti-β-actin antibodies were purchased
from Santa Cruz Biotechnology. The expression of β-
actin was used as loading control.
Statistical Analysis
Two-sided, Student's t-tests were used to analyze differ-
ences in protein levels between cancer and control sera. A
p value of less than 0.05 was considered statistically sig-
nificant (SPSS V11.0).
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Proteome differential expression in serum between 
pancreatic cancer patients and control
In this study, 2-DE was carried out with the serum sam-
ples taken from both the experimental and control
groups. The gels were digitized and analyzed by DeCyder
4.0 software.
Identification of differentially expressed proteins by MS/MS
In a pilot study, sera from 5 patients with pancreatic can-
cer were compared to the serum from 5 non-cancer-bear-
ing donors (Table 1). Samples were processed by
immuno-affinity depletion of the six most abundant
serum proteins. Differential protein analysis was then
performed using DIGE, as previously described. A total
of 1254 and 1251 protein spots were detected in the
experimental group and control group, respectively. Eight
protein spot-features were found to be up-regulated sig-
nificantly and eight were down-regulated significantly in
the sera of patients with pancreatic cancer (Figure 1).
All spot features of interest were trypsin-digested and
submitted to MS/MS for identification. MALDI-TOF MS
was used first for the identification of the protein spots.
The results indicated that protein spots (1158, 805, 800,
779 and 574) had the protein mass fingerprints (PMF)
and the corresponding proteins could be identified (Table
2). Protein spots (1105, 1161, 967, 902, 887, 804, 720 and
670) had protein mass finger prints, but did not corre-
spond to proteins in the NCBI Reference Sequence
human protein database. Then the LTQ-MS was used for
the identification of these protein spots. Five proteins
were identified as shown in the Table 3.
Elevated Levels of MBL2 and MLCK2 in pancreatic cancer 
serum
Up-regulation of serum MBL2 and MLCK2 in pancreatic
cancer was found by the DIGE and the 3 D spot images
were shown in Figure 2. Western blot analysis was then
performed for these two proteins in an independent set of
serum samples. Serum from 16 pancreatic cancer
patients and 16 non-caner-bearing controls were tested
(Table 4). Western blots showed the consistent over-
expressed of MBL2 and MLCK2 in individual pancreatic
cancer patients compared with individual non-cancer-
bearing donors (n = 16), and the Figure 3 showed the
western blot results of 16 pairs of the pancreatic cancer
sera and non-cancer-bearing controls' sera. Relative pro-
tein levels were then quantified using Imagequant soft-
ware (GE healthcare, Piscataway, NJ), and statistical
analysis was performed. Levels of these two proteins
tested were significantly higher in the serum samples
from cancer patients compared with controls (Figure 4, n
= 16, p < 0.05).
Discussion
Currently, effective methods for the early detection of
pancreatic cancer are still lacking. As a consequence,
most patients are diagnosed in the late stage of the dis-
ease and the subsequent treatment is palliative rather
than curative. At present, many serum markers for pan-
creatic cancer have been reported; including CEA, PNA-
binding glycoproteins [14], hTert(telomerase catalytic
subunit) [15] and matrix metalloproteinase-2(MMP-
2)[16]. These markers lack adequate sensitivity and speci-
ficity and have limited utility as an indicator for the early,
Table 1: Donor information of the sample set for DIGE
Casea Age Sex Tumor location Stageb
T1 51 M Head II
T2 50 M Head II
T3 62 F Tail III
T4 71 M Head II






aT: pancreatic cancer patients; N: non-cancer bearing donors.
bThe Union International Contre Le Cancer(UICC) classification.
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curative intervention, there is an urgent need to screen
better serum biomarkers for the early detection of pan-
creatic cancer. Theoretically, it would be preferable to
study patients exclusively in early stage disease; however,
most pancreatic cancer patients are in the advanced stage
when diagnosed. Therefore, some markers found in sera
from patients with advanced stage pancreatic cancer may
not be present in early stage cancer. It is reasonable to
conclude, however, that some markers detected in
advanced stage pancreatic cancer may also be present in
early stage disease [13].
However, there was a large scale of non-interest pro-
teins in the serum which made it difficult to analyze. In
this study, we used the immuno-affinity column to
remove the six most abundant proteins from serum sam-
ples. This technique proves to be both reproducible and
effective in removing these highly abundant proteins as
mentioned by Kenneth et al [13]. Immunoaffinity-
depleted serum samples from patients with pancreatic
Figure 1 Differentially expressed protein spots identified by DIGE analysis. Eight protein spot-features were found to be significantly up-regu-
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teen unique, differentially expressed proteins were identi-
fied by MALDI-TOF MS and LTQ MS. Further validation
studies in an independent set of serum samples from 16
pancreatic cancer patients and 16 non-cancer-bearing
controls demonstrated increased levels of MBL2 and
MLCK2.
However not every protein that was elevated in the
pilot study was validated in the independent set of serum
samples; for example, carbonic anhydrase 1 which failed
validation. It is not surprising that one or more of the
candidate biomarkers identified in our pilot study would
fail validation. This may have occurred for a few reasons.
Only five cancer patients and non-cancer-bearing con-
trols were analyzed in the pilot study. Differences among
such a small number of samples quite easily could be
unrelated to the disease state. One of the advantages of
using DIGE, compared to other separation techniques
such as multidimensional liquid chromatography, is that
different levels of one isoform or one post-translationally
modified form of a protein can be ascertained. These dif-
ferences, however, may prove difficult to confirm using
standard immunoblotting techniques, due to a lack of
specific antibodies. As in our study, spot 779 was an
unnamed protein and spot 800 and 805 could only be
identified by the cDNA sequence in the protein database.
Therefore it was difficult to validate these proteins and
identifying the function of these proteins might need fur-
ther study.
Proteomic analysis of serum protein profiles has
allowed researchers to identify new serum markers of
pancreatic cancer, but the identified proteins included
common serum proteins and components of the acute
phase response, which are not probably released from
tumors. MBL2, which was found in this study to be
increased in pancreatic cancer serum, has not been iden-
tified previously as a marker of pancreatic cancer. MBL2
is a calcium-dependent serum protein that plays a role in
the innate immune response by binding to carbohydrates
on the surface of a wide range of pathogens including
viruses, bacteria, fungi, and protozoa where it can acti-
vate the complement system or act directly as an opsonin
[17,18]. Recent studies found that polymorphisms in
MBL2 have been associated with various tumors. Wang
et al [19] reported that the codon 54 polymorphism of the
MBL2 gene was associated with more advanced pheno-
types of gastric cancer and the risk of gastric cancer in
Japanese patients at 65 years of age or younger. Pine et
Table 2: Identification results of proteins differentially expressed in pancreatic cancer patients and cancer-free control 
(MALDI-TOF MS)
Spot Protein name Accession no. MW pI Protein score Sequence Coverage Fold change (T/N) pValue
574 amplified in osteosarcoma 
isoform 1 precursor
gi|5803109 75971 4.80 70 14% -1.52 <0.05
779 unnamed protein product gi|1335344 70723 5.53 78 14% -2.05 <0.05
800 602153805F1 NIH_MGC_83 
Homo sapiens cDNA clone
gi|11953201 32115 9.15 91 30% -2.01 <0.05
805 AV723279 HTB Homo sapiens 
cDNA clone HTBAPBT7
gi|10826531 23047 9.77 98 24% -1.94 <0.05
1158 serum amyloid A4 gi|10835095 14854 9.27 92 40% -2.03 <0.05
Table 3: Identification results of proteins differentially expressed in pancreatic cancer patients and cancer-free control 
(LTQ-MS)
Spot Protein name Swiss-Prot ID MW pI Sequence coverage (%) Fold change(T/N) pValue
720 MYLK2 Myosin light chain kinase 2, 
skeletal/cardiac muscle
Q9H1R3 64684.86 6.6 1.68 2.30 <0.05
902 MBL2 Mannose-binding protein C 
precursor
P11226 26143.49 5.39 8.87 1.57 <0.05
967 CA1 Carbonic anhydrase 1 P00915 28870.18 6.59 10.73 1.61 <0.05
1105 HPR Isoform 1 of Haptoglobin-related 
protein precursor
P00739 39007.42 6.41 3.45 -2.64 <0.05
1161 SAA4 Serum amyloid A-4 protein 
precursor
P35542 14806.71 9.27 8.46 -2.69 <0.05
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MBL2 and MBL2 haplotypes and diplotypes appear to be
associated with lung cancer survival among Caucasian
patients. Caucasian lung cancer patients with low serum
MBL levels were statistically significantly associated with
improved survival time. In addition, the polymorphism of
MBL2 might have influence on the risk of breast cancer
in African-American women [21]. Another study, how-
ever, showed that the polymorphism of MBL2 had no
relation with the hepatic cancer [22]. In our study, we
showed for the first time that the serum levels of MBL2
were significantly higher in pancreatic cancer patients
than in the non-cancer-bearing controls (Figure 4A), sug-
gesting that MBL2 might represent a new serum marker
for pancreatic cancer. However, whether it is associated
with the development of pancreatic cancer need further
study.
MLCK2, a calcium/calmodulin (cam) dependent
enzyme, which expresses in adult skeletal muscle, was
expressed at a significantly higher level in sera from pan-
creatic cancer than in the non-cancer-bearing control
sera (Figure 4B). Thus, over-expression of this protein
was tumor-specific and might be used for early diagnosis
of pancreatic cancer. At present, there are few studies
associated with the MLCK2. However, as the isoform of
the MLCK2, MLCK has been studied extensively. MLCK
is responsible for smooth muscle cell and non-muscle cell
migration via phosphorylation of Ser19 and Thr18 on
myosin light chains (MLC), which could facilitate myosin
Table 4: Donor information for the validation set
Casea Age Sex Disease Stageb
T6 58 F Pancreatic adenocarcinoma IV
T7 53 M Pancreatic adenocarcinoma III
T8 64 M Pancreatic adenocarcinoma II
T9 51 M Pancreatic adenocarcinoma III
T10 64 F Pancreatic adenocarcinoma III
T11 81 M Pancreatic adenocarcinoma III
T12 59 M Pancreatic adenocarcinoma II
T13 63 M Pancreatic adenocarcinoma III
T14 69 M Pancreatic adenocarcinoma III
T15 48 M Pancreatic adenocarcinoma III
T16 67 M Pancreatic adenocarcinoma IV
T17 56 M Pancreatic adenocarcinoma IV
T18 37 F Pancreatic adenocarcinoma III
T19 58 F Pancreatic adenocarcinoma III
T20 52 F Pancreatic adenocarcinoma IV
T21 62 F Pancreatic adenocarcinoma I
N6 45 F Serous cystic pancreatic 
neoplasm
N7 54 F Somatostatin cell tumor
N8 60 M Islet cell tumor
N9 54 M Mucinous cystic pancreatic 
neoplasm
N10 36 M Pseudocyst
N11 36 F Serous cystic pancreatic 
neoplasm
N12 70 M Pseudocyst
N13 53 M Pancreatitis
N14 59 F Pancreatitis
N15 50 F Chronic pancreatitis
N16 48 F Intraductal papillary mucinous 
neoplasm
N17 37 F Normal
N18 54 M Normal
N19 64 M Normal
N20 72 M Normal
N21 56 F Normal
a T: pancreatic cancer patients; N: non-cancer bearing donors.
b The Union International Contre Le Cancer(UICC) classification.
Figure 2 3-D view of differentially expressed proteins. 3-D view of 
differentially expressed proteins in the serum of pancreatic cancer pa-
tients and the cancer-free controls. The computational analysis of the 
images with the DyCyder software allowed for the detection of signif-
icant abundance changes based on the variance of the mean change 
within the cohort. MBL2 (A) and MLCK2 (B) were over-expressed in the 
pancreatic cancer patients' serum. T: the pancreatic patients; N: the 
controls.
            T                      N 
A
B
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measured MLCK mRNA expression in tumor samples
from 39 non-small cell lung cancer (NSCLC) patients.
Their results showed that expression of MLCK was corre-
lated with disease recurrence and distant metastasis in
NSCLC [25]. Other researchers showed that inhibition of
MLCK by its inhibitor ML-7 could effectively retard the
proliferation and migration of the prostatic, breast and
pancreatic cancer cells. This suggested the possibility that
blocking of myosin II activity by a specific MLCK inhibi-
tor may be a therapeutic strategy for preventing the inva-
sion and metastasis of these tumors [26-28]. In
accordance with these findings, our proteomic results
suggested that MLCK2 might be a cancer-associated gene
and a novel tumor marker of pancreatic cancer. Thus, the
role of MLCK2 in carcinogenesis deserves further investi-
gation.
Conclusions
In the present study, we carried out DIGE proteomics
analysis on sera from pancreatic cancer patients and its
cancer-free controls. A total of 16 differentially expressed
proteins were identified, of which 8 were over-regulated
and 8 were under-regulated in the sera of pancreatic can-
cer patients. We further confirmed the expression levels
of two up-regulated proteins (MBL2 and MLCK2) in the
sera from pancreatic cancer patients using western blot
analysis. MBL2 and MLCK2 were identified for the first
time as serum biomarkers in pancreatic cancer. Serum
MBL2 and MLCK2 measurement might be helpful in dis-
criminating pancreatic adenocarcinoma from chronic
pancreatitis and healthy controls. The newly identified
proteins accompanied with the other serum biomarkers
(CEA and CA19-9) might be useful for the early diagnosis
of the pancreatic cancer.
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Figure 3 Western blot analysis. Western blot analysis confirms the DIGE findings of increased protein levels of MBL2 and MLCK2 in serum from pan-
creatic cancer patients (n = 16).
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Figure 4 The expression level of MBL2 and MLCK2. The expression 
level of MBL2 and MLCK2 was assessed by analyzing the intensity of its 
bands normalized with β-actin. Comparison of serum protein levels 
between patients with pancreatic cancer and the cancer-free controls 
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